Role of Melatonin in Aluminum-Related Neurodegenerative Disorders: a Review.
Esparza JL, Gómez M, Domingo JL.
Biol Trace Elem Res. 2019 Mar;188(1):60-67. doi: 10.1007/s12011-018-1372-4. Epub 2018 May 7.
Aluminum, parathyroid hormone, and osteomalacia.
Burnatowska-Hledin MA, Kaiser L, Mayor GH.
Spec Top Endocrinol Metab. 1983;5:201-26.
Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
Coburn JW, Norris KC.
Semin Nephrol. 1986 Dec;6(4 Suppl 1):12-21.
The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population.
Yuan B, Klein MH, Contiguglia RS, Mishell JL, Seligman PA, Miller NL, Molitoris BA, Alfrey AC, Shapiro JI.
Ren Fail. 1989;11(2-3):91-6. doi: 10.3109/08860228909066949.
The role of parathyroid function and parathyroidectomy in the outcome of aluminium-related dialysis encephalopathy.
Campistrus de Gencarelli N, Cournot-Witmer G, Zingraff J, Drüeke T.
Nephrol Dial Transplant. 1986;1(3):192-8.
Mechanisms of aluminum-induced microcytosis: lessons from accidental aluminum intoxication.
Caramelo CA, Cannata JB, Rodeles MR, Fernández Martín JL, Mosquera JR, Monzú B, Outeiriño J, Blum G, Andrea C, Lopez Farré AJ, et al.
Kidney Int. 1995 Jan;47(1):164-8. doi: 10.1038/ki.1995.19.
Continuous ambulatory peritoneal dialysis: three years' experience.
Ramos JM, Gokal R, Siamopolous K, Ward MK, Wilkinson R, Kerr DN.
Q J Med. 1983 Spring;52(206):165-86.
Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
Abreo K, Brown ST, Sella M, Trapp G.
J Lab Clin Med. 1989 Jan;113(1):50-7.
Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats.
Yamaguchi T, Baxter JG, Maebashi N, Asano T.
Ren Fail. 1999 Sep;21(5):453-68. doi: 10.3109/08860229909045184.
